Literature DB >> 14597977

The ACE D/D genotype is protective against the development of idiopathic deep vein thrombosis and pulmonary embolism.

Philip S Wells1, Marc A Rodger, Melissa A Forgie, Nicole J Langlois, Linlea Armstrong, Nancy L Carson, James Jaffey.   

Abstract

The deletion/deletion (D/D) genotype of the angiotensin converting enzyme (ACE) has been purported to be a risk for post-operative thrombosis.This D/D genotype has not been evaluated as a risk factor for idiopathic venous thromboembolism (VTE). The primary objective of the present study was to determine whether the D/D genotype of ACE is independently associated with the occurrence of idiopathic venous thromboembolic disease. We prospectively enrolled consecutive patients with at least one objectively confirmed idiopathic VTE. Friends of cases were recruited as controls and matched to cases by sex, ethnicity, and age. Patients were tested for the ACE I/D polymorphism in addition to factor V Leiden, prothrombin G20210A, and factor VIII levels. Three hundred cases and 300 controls were enrolled; 97% were Caucasian. There were 148 females and 152 males in each group with a mean age of 56.21 years (SD = 15.33). The ACE D/D genotype was present in 25.3% of cases and 32.4% of controls for an adjusted odds ratio of 0.66 (95% CI = 0.433 to 0.997). We can conclude that the ACE D/D genotype is protective against idiopathic venous thromboembolism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14597977     DOI: 10.1160/TH03-03-0170

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  5 in total

1.  Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls.

Authors:  Benedetto Simone; Valerio De Stefano; Emanuele Leoncini; Jeppe Zacho; Ida Martinelli; Joseph Emmerich; Elena Rossi; Aaron R Folsom; Wassim Y Almawi; Pierre Y Scarabin; Martin den Heijer; Mary Cushman; Silvana Penco; Amparo Vaya; Pantep Angchaisuksiri; Gulfer Okumus; Donato Gemmati; Simona Cima; Nejat Akar; Kivilcim I Oguzulgen; Véronique Ducros; Christoph Lichy; Consuelo Fernandez-Miranda; Andrzej Szczeklik; José A Nieto; Jose Domingo Torres; Véronique Le Cam-Duchez; Petar Ivanov; Carlos Cantu-Brito; Veronika M Shmeleva; Mojka Stegnar; Dotun Ogunyemi; Suhair S Eid; Nicola Nicolotti; Emma De Feo; Walter Ricciardi; Stefania Boccia
Journal:  Eur J Epidemiol       Date:  2013-07-31       Impact factor: 8.082

Review 2.  Angiotensin-converting enzyme gene polymorphism and allele frequencies in the Lebanese population: prevalence and review of the literature.

Authors:  Amira S Sabbagh; Zaher K Otrock; Ziyad R Mahfoud; Ghazi S Zaatari; Rami A R Mahfouz
Journal:  Mol Biol Rep       Date:  2006-11-11       Impact factor: 2.316

3.  Cardiovascular risk associated with interactions among polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems.

Authors:  John P Bentley; Folkert W Asselbergs; Christopher S Coffey; Patricia R Hebert; Jason H Moore; Hans L Hillege; Wiek H van Gilst
Journal:  PLoS One       Date:  2010-09-15       Impact factor: 3.240

4.  A pilot study to assess the feasibility of a multicenter cluster randomized trial for the management of asymptomatic persons with a thrombophilia.

Authors:  Philip S Wells; Martha L Louzada; Monica Taljaard; David R Anderson; Susan R Kahn; Nicole J Langlois; Julie Rutberg; Michael J Kovacs; Marc A Rodger
Journal:  J Genet Couns       Date:  2009-06-03       Impact factor: 2.537

5.  Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy.

Authors:  Marc A Rodger; Susan R Kahn; Philip S Wells; David A Anderson; Isabelle Chagnon; Grégoire Le Gal; Susan Solymoss; Mark Crowther; Arnaud Perrier; Richard White; Linda Vickars; Tim Ramsay; Marisol T Betancourt; Michael J Kovacs
Journal:  CMAJ       Date:  2008-08-26       Impact factor: 8.262

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.